When a tumor is surgically removed today, tiny amounts of residual cancer cells may remain at a level that is undetectable with imaging or current blood-based technologies. Due to this uncertainty:
A blood test that can detect and quantify tiny amounts of residual cancer to better monitor cancer treatment, progression, and recurrence. C2i’s ultra-sensitive test enables high precision personalized medicine, reduced cancer treatment costs, and accelerated drug development.
Learn more about our scienceUtilizing our platform, our technology is accessible anywhere in the world, bringing high precision personalized cancer monitoring to a growing number of locations on the map.
Learn more
Personalized treatment decision and monitoring with multiple applications throughout the clinical timeline of a patient’s cancer treatment.
Learn more
Partner with us to utilize our MRD monitoring and cancer Intelligence Platform in your clinical trials and research. Accelerating clinical trials with accurate enrollment and highly sensitive and specific surrogate endpoints.
Learn more
C2i’s executive team brings together decades of experience across military intelligence and biotech companies including the New York Genome Center, Bristol-Myers Squibb, GlaxoSmithKline, Tempus, Foundation Medicine, and Amwell.
Join us in empowering researchers, physicians and patients with ultra-sensitive cancer detection.
